• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Bausch & Lomb offers aberration-free accommodating IOL with aspheric optics

Article

Bausch & Lomb has announced the launch of the first aberration-free accommodating IOL with aspheric optics (Crystalens AO) to cataract surgeons worldwide.

Aliso Viejo, CA

-Bausch & Lomb has announced the launch of the first aberration-free accommodating IOL with aspheric optics (Crystalens AO) to cataract surgeons worldwide.

The lens has prolate aspheric surfaces and is designed to be free of spherical aberration, the company said in a prepared statement. The IOL is designed to improve retinal image quality without compromising depth of field and, therefore, it provides greater quality of distance and intermediate vision, according to a company statement.

“Some surgeons might assume because the Crystalens has aspheric optics, depth of field will be reduced. However, our comprehensive testing demonstrates the opposite to be true,” said Andy Corley, global president, Surgical, Bausch & Lomb. “Not all aspheric lenses are created the same, and other aspheric IOLs have negative spherical aberration, which could reduce depth of field. The Crystalens AO has zero spherical aberration, and the combination of the Crystalens platform and AO optics work[s] together to enhance depth of field.”

“We know that many surgeons prefer aspheric lenses because they believe that they correct for spherical aberrations and provide better quality of vision,” said Amy Jacobs, director of global marketing for the Crystalens.

The aspheric optic lens is composed of proprietary biosil silicone and has a thin and uninterrupted barrier edge. It will be inserted using an injector (CI-28) in a controlled manner through an unenlarged phaco incision, a routine requirement in today’s cataract surgical procedure.

The worldwide launch of the IOL is expected to accelerate through the first quarter of 2010, according to the company.

Related Videos
Neda Nikpoor, MD, talks about the Light Adjustable Lens at ASCRS 2024
Elizabeth Yeu, MD, highlights from a corneal case report for a patient undergoing the triple procedure
William F. Wiley, MD, shares some key takeaways from his ASCRS presentation on binocularity and aperture optics.
© 2024 MJH Life Sciences

All rights reserved.